



Author Correction: Trends in kinase drug discovery: targets, indications and inhibitor design

Misty M. Attwood , Dorian Fabbro, Aleksandr V. Sokolov, Stefan Knapp  and Helgi B. Schiöth

Correction to: *Nature Reviews Drug Discovery* <https://doi.org/10.1038/s41573-021-00252-y>, published online 5 August 2021.

Errors in the description of side effects reported for the kinase inhibitor deucravacitinib have been corrected.

<https://doi.org/10.1038/s41573-021-00303-4> | Published online 2 September 2021

© Springer Nature Limited 2021

Author Correction: PI3K inhibitors are finally coming of age

Bart Vanhaesebroeck , Matthew W. D. Perry , Jennifer R. Brown , Fabrice André  and Klaus Okkenhaug 

Correction to: *Nature Reviews Drug Discovery* <https://doi.org/10.1038/s41573-021-00209-1>, published online 14 June 2021.

Some minor inaccuracies regarding the characteristics and clinical trials of alpelisib have been corrected.

<https://doi.org/10.1038/s41573-021-00300-7> | Published online 1 September 2021

© Springer Nature Limited 2021
